GENZYME GAINS 52-PERSON U.S. DIRECT SALES FORCE FOR SEPRAFILM, SEPRACOAT SURGICAL ADHESION PRODUCTS THROUGH $250 MIL. DEKNATEL SNOWDEN PENCER ACQUISITION
This article was originally published in The Gray Sheet
Executive Summary
Genzyme's $250 mil. acquisition of Deknatel Snowden Pencer, driven by the desire to gain an established U.S. sales force for the Seprafilm and Sepracoat hyaluronic acid-based surgical adhesion prevention products, also moves the biotech firm into a new business area -- surgical instrumentation.